Xtant Medical Raises FY2026 Sales Guidance from $95.000M-$99.000M to $101.000M-$105.000M vs $96.725M Est
Benzinga Newsdesk 5 months ago
NewsGuidance
2026 Financial GuidanceThe Company is today increasing its full-year 2026 revenue guidance to a range of $101 million to $105 million, from $95 million to $99 million previously, to reflect the recently announced
2026 Financial Guidance
The Company is today increasing its full-year 2026 revenue guidance to a range of $101 million to $105 million, from $95 million to $99 million previously, to reflect the recently announced exclusive license agreement with Dilon Technologies and anticipated incremental revenue contribution from Dilon's HEMOBLAST® Bellows.